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Abstract
Several investigators have shown the utility of systemically delivered optical imaging probes to image tumors in small
animal models of cancer. Here we demonstrate an innovative method for imaging tumors and tumor margins during
surgery. Specifically, we show that optical imaging probes topically applied to tumors and surrounding normal tissue rapidly
differentiate between tissues. In contrast to systemic delivery of optical imaging probes which label tumors uniformly over
time, topical probe application results in rapid and robust probe activation that is detectable as early as 5 minutes following
application. Importantly, labeling is primarily associated with peri-tumor spaces. This methodology provides a means for
rapid visualization of tumor and potentially infiltrating tumor cells and has potential applications for directed surgical
excision of tumor tissues. Furthermore, this technology could find use in surgical resections for any tumors having
differential regulation of cysteine cathepsin activity.
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Introduction
In 2008, an estimated 21,000 men and women were diagnosed
with cancer of the brain [1]. Of these, glioblastoma multiforme
(GBM) is the most common, accounting for 31% of all tumors and
80% of malignant brain tumors (CBTRUS, 2011, http://www.
cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf).
These types of tumors present as focal masses with margins
infiltrating the brain parenchyma. The current treatment for
malignant brain tumors includes surgical excision (if possible) of
the neoplastic mass followed by radiation of the resection cavity
and often adjuvant chemotherapy to help prevent recurrence.
However, despite decades of research efforts these measures have
only minimally increased the average lifespan of patients [2].
Therefore the development of novel approaches that can be used
to refine current approaches for diagnosis and treatment of these
cancers remains imperative.
Several technological advances have been developed which
improve the quality and efficacy of brain tumor surgery. These
include microscopic and MRI enhanced surgery and intraoper-
ative fluorescence-guided surgery, although the latter is not yet
clinically available in the United States [3,4]. In 1997 Black
introduced MRI based intraoperative imaging (IOI) as an
improvement over microscopic surgery alone [5] and in 1999
Knauth et al. demonstrated that IOI MRI was effective at
decreasing tumor burden [6,7,8,9]. More recently, clinical trials in
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3Europe have begun to use fluorescence guided surgical techniques
to achieve more complete tumor resections [3]. Stummer et al. has
demonstrated that 5-ALA fluorescence-guided resection of GBM
results in statistically significant increase in complete resections of
the tumor, as judged by post-operative MRI, compared to white
light resected patients which was correlated with an increase in 6-
month progression free survival [3]. This study did not show a
long-term increase in survival, but was not powered to do so.
Interestingly, advances in neurosurgical techniques have proven to
be the most effective method of altering the natural progression of
brain cancer, even compared to advances in chemotherapy. A
number of studies show a significant correlation between improved
resection efficacy and increased patient survival and better quality
of life [10] [9,11,12]. However, these MRI/fluorescence guided
‘‘complete resections’’ obviously are not removing all the tumor
tissue and do not affect cures. With current ‘‘complete resections’’
(MRI negative images post-operatively) there is a statistically
significant increase of approximately 5.1 months in patient survival
but cures are not achieved [10]. This surgical failure is partially
related to probe bioavailability and image resolution, both of
which limit the ability of current imaging techniques to accurately
define tumor margins and determine the extent of infiltrating cells
during surgery. Further, invasive tumor tissues, even if visible, are
sometimes not possible to remove without causing significant
patient deficits. Therefore, the goal for surgical resection of GBM
likely will be to achieve maximal de-bulking of the tumor resulting
in extended patient survival [10] thereby potentially increasing the
efficacy of adjuvant therapies. A large EORTC study showed that
patients with complete resection benefit most strongly from
concomitant radiotherapy with temozolomide [13], thus giving a
further incentive for maximum resection. To advance the efficacy
of brain tumor resection, it will be necessary to clearly identify and
remove margin-penetrating cells. Intraoperative microscopic
techniques combined with molecular imaging probes specific for tumor
markers could play a significant role in future surgical and
therapeutic approaches. Here we present studies using molecular
imaging that exploit tumor associated proteases as markers for
identification of tumor tissues.
Upregulation of proteases in cancers is a well documented
phenomenon [14]. Several families of cysteine proteases are
consistently over-expressed in many types of cancers [15,16]. In
particular, the papain family cysteine proteases cathepsins B and L
exhibit increased activity in most cancers [17], have significantly
increased expression and activity in GBMs [18,19,20], and have
the highest degree of expression at the tumor - brain interface
[21,22].
Several investigators have successfully developed fluorescent
molecular imaging probes to image disease-associated proteases
[23,24,25,26]. More recently these imaging technologies have
been further developed to enable image-guided resections of
tumors [27,28,29]. Most of the non-invasive NIRF imaging probes
developed to date are fluorescently quenched substrate based
probes and rely on a consensus peptide sequence to serve as an
enzyme substrate allowing for probe activation. Here we employ
fluorescently quenched activity based probes (ABP) that are based
on small molecule suicide inhibitors of tumor-associated proteases.
Upon interaction of the probe with its enzyme target it undergoes
a bond rearrangement resulting in the loss of the quenching
moiety (probe activation) and covalent modification of the active-
site cysteine of the protease causing enzyme inhibition and
‘‘linking’’ of the fluorochrome to its target [23]. The stability of the
covalent modification of the targeted enzyme presumably keeps
the fluorochrome from washing away from the site where it was
unquenched making these probes as effective as substrate-based
probes, which take advantage of enzymatic activity to amplify the
signal by activating more than one probe, but can have significant
washout of liberated fluorochromes [30]. Additional benefits of the
covalent ABP probes are that they provide higher protease
selectivity than do substrate probes and allow direct SDS-PAGE
evaluation of labeled targets [23,31]. Furthermore, these probes
rapidly penetrate cells and become activated both in vitro and in vivo
[23,31].
We present the use of fluorescently quenched activity based
probes as novel intra-operative molecular imaging tools for
identification of tumor margins and infiltrating tumor cells.
Specifically, we have demonstrated that quenched ABPs can be
formulated for topical administration, that topically administered
probe is activated within minutes by specific cathepsin proteases
and that topical administration highlights tumor margins and
small clumps of tumor cells as compared to systemically
administered probes. Finally, we demonstrate that human GBM
biopsies also rapidly activate the probe supporting the argument
that this technology has the potential to improve surgical resection
of brain tumors. We envision that this technology will provide
significant value in the improvement of tissue-sparing procedures,
such as brain tumor resections.
Results
In order to establish a brain tumor model system that would be
suitable for imaging using the ABP probes, we evaluated levels of
active cathepsins in the human brain tumor cell line Gli36-
D5EGFR relative to a previously analyzed mouse cell line known
to exhibit high cysteine cathepsin levels (C2C12/Hras1) (22).
Labeling of intact cells with either the quenched activity based
probe (qABP) GB119 or the non-quenched version of the probe,
GB123, followed by SDS-PAGE and Typhoon scanning (22)
indicated that GB123 labeled both human and mouse cathepsin L
(Cat L) and cathepsin B (Cat B), as reported previously for other
cells (22). GB119, however, was much more selective for Cat L
with little to no labeling of Cat B in mouse or human tissue culture
cells. Selectivity of labeling was further confirmed by observing the
loss of labeling in cells pre-incubated with a broad-spectrum
cathepsin inhibitor, JPM-OEt, (Fig. 1 a–b). An additional 66 kD
protein which was labeled strongly with GB123 but only weakly
with GB119, was identified via mass spectrometry as a non-specific
interaction of the probe with serum albumin (data not shown). The
control probe, GB125, which contains the Cy5 fluorescence label
with a non-reactive amide in place of the acyloxymethylketone
(AOMK) ‘‘warhead’’(22), also strongly labeled this band further
supporting the non-specific nature of the interaction. This
background signal is reduced in the samples treated with GB119
because albumin cannot activate the quenched probe.
We next determined if GB119 could be activated by cysteine
cathepsins within a solid tumor following topical application ex vivo.
Tumors derived from Gli36D5EGFR cells were excised, surgically
divided, bathed in 10 mM GB119 or vehicle control and analyzed
biochemically as above (Fig. 1c). Consistent with the in vitro cell
labeling data, the probe penetrated the tissue and efficiently
labeled both the single and heavy chain forms of Cat L, with less
labeling on Cat B. The signal appeared to plateau at 20 minutes
with a decrease in signal strength at 25 and 30 minutes, perhaps
due to the lack of extended viability of the tissue in this ex vivo
setting.
We next sought to test the utility of topical application to
specifically identify tumor proteases in vivo. Gli36D5EGFR cells
were used to form flank tumors in nude mice. When tumors were
10–12 days old GB119 was topically applied to the exposed tumor
Topical Application of ABPs
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imaging (Fig. 2a). GB119 was rapidly activated with signal
detected in as little as 1 minute with continued accumulation up to
30 minutes. Washing and re-imaging of the region of initial probe
application decreased signal by nearly 60%, presumably due to
removal of secreted labeled-proteases. However, the remaining
signal remained statistically significant relative to the control (p-
value=0.0005). To test the in vivo specificity we topically treated
tissues with either GB119 alone (P) or a mixture of GB119 and
GB111-NH2, an inhibitor of Cat L and B [23], at 100-fold excess
of (P+I) (Fig. 2b). In these studies small pieces of tumor were
surgically removed to create cavities in the tumor to ensure that
the applied treatments were unable to inadvertently combine
(inset, Fig. 2b). Animals were imaged every 5 minutes for
30 minutes at which time the cavities were washed and re-imaged
at 35 minutes. Inclusion of the inhibitor during incubation
reduced probe activation by 74.5%. To better understand the
specificity of the tissue labeling, GB119 was topically added to
flank tumors in vivo and the resulting fluorescing tissue was
removed and subjected to SDS-PAGE analysis. These studies
showed that in vivo GB119 retained its specificity to label Cat L
(figure S1). Further studies with a broad spectrum cathepsin
Figure 1. GB119 specifically labels cells in vitro and tumor tissue ex vivo. (a) Gli36D5EGFR cells were incubated with JPM-OEt, a general
papain-family inhibitor (+, lanes 2,4 and 6) or 0.1% DMSO vehicle control (2, lanes 1,3 and 5) before the addition of the indicated probe GB119,
GB123, or GB125 (the control probe, GB125, contains the Cy5 fluorescence label with a non-reactive amide in place of the acyloxymethylketone
(AOMK) ‘‘warhead’’(22)). (b) In vitro cell labeling with NIRF-APBs. C2C12/ras cells were incubated with JPM-OEt, a general papain-family inhibitor (+)o r
0.1% DMSO as a vehicle control (2) before the addition of the indicated probe. Samples were analyzed by SDS-PAGE and Cy5 fluorescence was
measured by scanning the gels with a Typhoon scanner. Specific bands are indicated as follows: cathepsin L single-chain form (Cat L sc); cathepsin L
heavy-chain (Cat L hc), and cathepsin B (Cat B). (c) Gli36D5EGFR flank tumor tissue was immersed in GB119 for the indicated time or DMSO vehicle
control (D) for 30 minutes. Specific cathepsin bands are indicated as follows: cathepsin L single-chain form (Cat L sc,); cathepsin L heavy-chain (CatL
hc); and cathepsin B (Cat B).
doi:10.1371/journal.pone.0033060.g001
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probe was protease specific (data not shown). As expected, similar
topical in vivo studies using non-quenched ABPs, such as GB123,
suffered from high background levels, which could not be
removed, and tumor tissue could, therefore, not be resolved from
background.
Next, we assessed the ability of the probes to discriminate
tumor tissue from normal brain tissue in a mouse orthotopic
brain tumor model. For these studies mice were unilaterally
stereotactically implanted with Gli36D5EGFR cells (Fig. 3a,t o p
panel). When tumors were 10–12 days old, animals were
sacrificed, the brains removed and sectioned into 2 mm thick
coronal sections. Only the brain sections containing visible tumor
(arrow, Fig. 3a) were used in these studies (3–5 slices/brain, total
of 20 slices). Age matched normal mouse brains or sham
implanted brains were used as controls for background activation
of the probe (Fig. 3a, lower panel). After obtaining base-line
fluorescent image of the slices, we topically applied GB119 to
both hemispheres of the brain slice. The tumor-containing
hemisphere of brain consistently and rapidly activated the probe,
and activation was always observed at the tumor-brain interface.
Neither the contralateral hemisphere nor the normal matched
control slices activated GB119 (Fig. 3a,b). The slices were
washed after 30 minutes and re-imaged at 35 minutes to
determine the stability of the signal. These manipulations
demonstrated that the signal intensity was stable but that
Figure 2. Topical application of GB119 to heterotopic brain tumors results in rapid and specific in vivo activation of the probe. (a)
Mice bearing Gli36D5EGFR flank tumors (n=12) were treated with GB119 and imaged over time. The mean +/2 standard deviation is plotted vs. time.
Wilcoxon signed ranked test showed that the signal increased significantly above the time 0 signal at each of the times 1, 5, 15, 30, and 35 (p=0.0005
at each time point). Inset is a representative mouse treated topically with GB119 and imaged across time. (b) Percent inhibition of GB119 activity by
GB111-NH2 was determined for each mouse (n=4) and is presented as mean +/2 standard deviation at 35 minutes. There was significant reduction
in the signals when incubated with both GB119 and inhibitor at all time points except time 0 (two-sample t-test p,0.05). Inset represents GB119 (P)
or a mixture of GB119 with 100-fold excess of GB111-NH2 (P+I) at 35 minutes after treatment. Images are unmixed false colored maps of pixel
intensity representing activated GB119.
doi:10.1371/journal.pone.0033060.g002
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confirmed specificity of probe labeling by co-treatment with
protease inhibitor and GB119 (Fig. 3c,d).
For a subset of the tumor-bearing brains where the tumor was
visible on the dorsal surface of the brain no sectioning was
performed (n=6). Instead we removed the brain and applied the
probe directly to the tumor and surrounding tissue, and as a
control, probe was also applied to a similar sized area on the
contralateral hemisphere (Fig. 4a, outlines). Only probe applica-
tion to the tumor side resulted in signal, which was detectable by
5 minutes and continued to increase over time (Fig. 4b). Again,
activation was largely localized to the tumor-brain interface
(Fig. 4b). To further resolve which tissue was associated with
activated probe, the brains were fixed in paraformaldehyde and
subjected them to immunohistochemistry and fluorescence
microscopy. These studies showed the majority of activated probe
(false colored red) was associated with vimentin-positive human
tumor cells (false colored green), with the greatest extent of
activation being present at the tumor margin (Fig. 4e,f) and
associated with either human or mouse Cat L expression (figure
S2). The Cy5 fluorescence of the probe at the margins, however,
appeared more diffuse than the punctate staining noted within the
tumor mass itself, and may be the result of activation of secreted
proteases into the interstitial space at the tumor margin as well as
an effect of epifluorescence resulting from GB119-labeled cells in
different planes within the 25 micron thick sections used in this
particular experiment (Fig. 4e, arrows). Notably, GB119 was able
to recognize a vimentin-positive cell outside of the main tumor
mass (Fig. 4f, arrowhead), i.e. infiltrating tumor cells. Using
Image J we were able to quantify the fluorescence from cells
located within the tumor center or at its edge. These data
suggested more probe activation occurred in cells located at the
Figure 3. Ex vivo activation of GB119 in orthotopic brain tumors. (a) Representative 2-mm sections from normal and tumor-bearing brains
(see arrow for main tumor mass). Monochromatic images are shown on left and unmixed false colored maps of pixel intensity representing activated
GB119 at 35 minutes are shown on the right. (b) The averages of total signal/area/volume from the slices for each animal is plotted over time for
normal (n=3) and tumor (n=6) groups. The groups did not differ at time 0 (p=0.65). Using Bonferroni correction with overall significance level 0.05,
the groups differed significantly at times 5, 15, 30 and 35 minutes. (c) Inhibition of GB119 activation in an orthotopic brain tumor model using
opposing brain slices (opened like a book) containing tumor (arrow, n=11). (d) Percent inhibition of GB119 activity was determined for each mouse
and is presented as mean +/2 standard deviation at 35 minutes. Using Bonferroni correction for multiple testing at times the groups did not differ at
time 0 (p=0.86) but differed significantly at times 1, 15, 30 and 35 minutes (p,0.0003). Scale bar, 5 mm.
doi:10.1371/journal.pone.0033060.g003
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p=0.124 (Fig. 4g). Interestingly, immunostaining of these
sections for a microglial and macrophage marker, CD11b,
suggested that some but not all of the tumor-associated signal
resulted from microglial activation of the probe (note co-
registration of microglial and GB119 Cy5 signals (Fig. 4h).
Microglial activation of probe only occurred in microglial cells that
were tumor associated. High concentrations of microglial cells in
normal brain adjacent to the tumor did not activate the probe
(Fig. 4i).
Figure 4. Topical application of GB119 to a brain tumor on the dorsal surface labels the tumor’s edge more robustly than the
tumor’s center. (a) Monochromatic image of a whole brain with a tumor growing near the dorsal surface (arrow) showing the treated areas
(outlines). (b) Unmixed false colored map of pixel intensity representing activated GB119 at 35 minutes post application. (c) Horizontal H&E stained
section showing higher magnification of square area in panel b demonstrating tumor mass and normal surrounding brain. (d) Adjacent sections
revealing human vimentin positive cells labeling tumor edge and center (false colored green), (e) activated GB119 (Cy5, false colored red) revealing
infiltrating cells, the tumor margin and to a lesser degree the interior of the tumor and (f) merged imaged demonstrating co-registration (yellow) of
GB119-labeled cells and vimentin positive cells within the tumor mass (arrows) and outside of the main tumor mass, arrow head. (g) GB119 labeled
cells at the tumor’s edge more robustly than at the tumor’s center, although not significantly, p=0.124. (h and i) reveal that GB119 is associated with
CD11b-positive cells, but only when they are tumor associated, (h) is a typical image observed from within the tumor interior and (i) shows the
images typical of the tumor – brain interface. Note that only CD11b positive cells associated with normal brain do not activate the probe. Section
thickness 25 mm( d–f) and 10 mm( h,i). Scale bar, 5 mm( a,b), and 100 mm( c–f, h,i).
doi:10.1371/journal.pone.0033060.g004
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and 4) was in contrast to other studies where IV injection of
GB137 and GB123 showed signal uniformly throughout flank
tumors [31]. To determine if the route of administration or the
implantation site altered the pattern of staining we directly
compared imaging of orthotopic brain tumors using systemically
administered GB123 or topically administered GB119 (GB119 is
not stable for IV injection [23,31]). Both probes were able to
define the tumor, but the pattern of Cy5 fluorescence was not
identical (Fig. 5). In both whole brain and brain slice models, low
resolution imaging using the Maestro system suggested that
systemically administered GB123 probe appeared to uniformly
label the entire tumor mass (Fig. 5b,d). This was in contrast to the
edge labeling detected when GB119 probe was topically applied
(Fig. 5a,c). Histologic evaluation of sections from these tumors
indicated that systemic administration of the probe primarily
labeled cells within the interstitial spaces of the tumor mass
(Fig. 5h) while not highlighting the tumor edge (Fig. 5j). In
contrast, tissues probed topically with GB119 showed punctate
staining within the tumor mass, primarily associated with tumor
cells (Fig. 5g), and reproducibly highlighted the peri-tumor space
and tumor cells and CD11
+ cells within that space (Fig. 5i).
To more precisely represent the signal intensity between GB119
and GB123 we quantified the probe fluorescence in microscopic
sections using Image J. Quantification and statistical comparison
of the signal measured from the center of tumors labeled with
topical GB119 or from the center of tumors labeled with
systemically administered GB123 revealed that there was no
statistical difference between the signal intensity. In contrast, the
signal resulting from the edge of GB119 treated tumors was 12-
fold greater than that coming from GB123 treated tumors and did
reach statistical significance, p.0.05. Remarkably, in a subset of
animals where some tumor cells had moved throughout the brain,
presumably migrating along either the ventricular system or the
meninges, topically administered GB119 robustly identified these
cells and clusters (Fig. 5k,m), while systemically administered
GB123 did not in other animals (Fig. 5l,n).
We also sought to determine if topical application of probe to
surgically resected tumors could be utilized to identify tumor
tissues that were ‘‘missed’’ during the resection. In animals where
the tumor grew to the dorsal surface of the brain the tumors were
removed and the resection cavity was filled with GB119. This
resulted in activation of GB119 (Fig. 6a) in each case (N=5). The
brains were then sectioned and the fluorescing tissue identified
(Fig. 6b and c). Only remaining tumor tissue fluoresced, while
normal brain was devoid of signal. As is evident from Fig. 6,
topical application of the probe only results in a partial penetration
into tumor tissue.
The final step in these studies was to demonstrate that topically
administered GB119 could also be activated by GBM tissue
derived from human patients. Discarded human GBM tissue was
obtained from the operating room and treated with GB119 within
30 minutes of resection. Robust activation of the probe was
measured in 14 out of 15 patients in as little as 5 minutes.
Activation continued for at least 30 minutes, although varying
degrees of activation was measured among different tumor pieces
(Fig. 7a). In a single surgical case, resection of the tumor mass also
provided samples of non-tumor human brain, or ‘‘normal brain’’.
Probing of this patient’s tumor and matched ‘‘normal brain’’ tissue
demonstrated a significant activation of GB119 by tumor tissue
with little activation by the ‘‘normal’’ brain tissue (Fig. 7b). Since
the results from our orthotopic model (figure S2) and reports in
the literature indicate that Cat L protease expression/activity is
upregulated at the tumor margins, we examined directed biopsies
for probe activation. Patient tissue samples from both the edge and
center of the tumor, as defined by the surgeon, were obtained from
five patients and imaged over time as previously described. Within
this set of samples, eight out of ten rapidly activated the probe,
with greater activation in the edge samples from four of the five
patients. The two samples that did not show activation were both
biopsies from the center of the tumor (Fig. 7c). These data suggest
that there is heterogeneity of protease expression both within and
between tumors. However this finding did not reach statistical
significance with our limited sampling.
Discussion
Currently, there is a significant need for new imaging tools that
can be used to define tumor margins during the process of surgical
resection. While many new approaches have been developed that
make use of various affinity reagents and enzyme substrates and
have demonstrated utility in animal models, only one targeted
probe has been demonstrated for real-time intra-operative
molecular imaging applications in humans [28,32]. Here we
demonstrate an alternative application of fluorescently quenched
activity based probes, which can be used topically to identify
tumor tissues. These reagents are sufficiently small and hydro-
phobic so that they can be applied topically and freely penetrate
into associated tissues. In addition, because the probes are able to
covalently label their target proteases, it is possible to use direct
biochemical methods to confirm the specificity of probe labeling.
In this study we demonstrate the utility of this approach for
visualization and potential better resection of human brain tumors,
but envision an expanded set of applications in other tumor
systems that express high levels of cysteine cathepsin activity.
Glioblastoma multiforme is one of the most lethal human
cancers. Technological advances in brain surgery have signifi-
cantly impacted patient survival and quality of life [10,12,33]. To
further advance image guided brain tumor resection, several
groups are now pursuing fluorescent dyes or drugs (especially
photodynamic therapy agents) to label tumors. Attempts to
improve tumor resections include applications of non-targeted
fluorescent probes [34,35,36], targeted agents, such as quantum
dots [37] or labeled peptides [38] and substrate based imaging
probes [39,40,41]. Most recently a first in human trial has
demonstrated the feasibility of a targeted imaging agent to
elaborate disseminated ovarian cancer in real-time during surgery
[28]. However, these trials still have to demonstrate an impact on
patient survival.
A trial investigating orally administered 5-ALA, a photodynam-
ic therapeutic, to guide surgical resection of brain tumors has
demonstrated that fluorescence-guided resections result in better
brain tumor removal with an increase in MRI-negative post-
operative scans and an increase in disease free survival at 6 months
[3]. However, delivery of 5-ALA into brain tissue is non-uniform
because it depends on a leaky blood brain barrier. This combined
with a sometimes weak fluorescent signal from tumor tissues and/
or high fluorescent backgrounds, can confound identification of
tumor tissue during surgery. Furthermore, 5-ALA patients remain
photosensitive after administration.
GB119 is a hydrophobic small molecule quenched optical
imaging probe that produces virtually no fluorescence signals in
tissues that do not express active cathepsin proteases. This
characteristic allows for topical application and results in rapid
and robust identification of even very small amounts of tissue-
associated protease activity. We present data demonstrating that
topical application of GB119 can rapidly identify peri-tumor
spaces and margins, including cells that were not detectable by systemic
Topical Application of ABPs
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technology presented solves many of the problems faced by
systemically administered probes (e.g. 5-ALA and FITC–labeled
probes). Namely, 1) GB119 is labeled with a Cy5 dye that
fluoresces in the near-infrared region of the spectrum, potentially
eliminating much of the auto-fluorescence background encoun-
Figure 5. Comparison of tumor cell labeling between topical application of GB119 and systemic administration of GB123. (a–d)
Representative unmixed false colored maps of pixel intensity of coronal 2 mm sections (a,b) and dorsal surface tumors (c,d) comparing the pattern of
activation of topical GB119 (left side) and systemic GB123 (right side). (e,f) H&E coronal sections demonstrating tumor mass. (g–j) Merged fluorescent
microscopy of adjacent sections showing labeling in the center (g,h) and edge (I,j) of the tumor. Sections were immunostained with anti-human
vimentin antibody to reveal the brain tumor xenograft (false colored green), covalently bound Cy5 (false colored red). Yellow represents co-localized
staining. (k&i ) H&E sections demonstrating tumor cells that migrated away from the main tumor mass (outlined) via the ventricular system (k)o r
along the cortical meninges (i). Boxed regions indicate invading cells (m & n). Merged images of boxed regions from panels k & i showing labeling of
invading tumor cells. Vimentin positive tumor cells (false colored green) and Cy5 cells (false colored red) reveals that invading cells were identified by
topical GB119 (yellow cells) (m) but not by systemic GB123 (n). DAPI staining for cellular orientation was also included in panels m,n. Scale bar, 1 mm
(e,f), 500 mm( k,l), and 50 mm( g–j, m, n).
doi:10.1371/journal.pone.0033060.g005
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GB119 can be directly and uniformly applied to unidentifiable
tissue during the surgical procedure and is immediately bioavail-
able, even to tissues with poor vascularization, elaborating tumor
tissues from normal tissues in 5–10 minutes; 3) Topical adminis-
tration appears to be more effective than systemic administration
for identification of small clumps of tumor cells.
Our studies demonstrate that the pattern of probe activation is
dependent on the mode of administration. With systemically
administered agents the pattern of probe activation was uniform
and limited to the tumor mass. In contrast, topical administration
of probe consistently produced an activation pattern that was
primarily associated with the peri-tumor space.
Immunohistochemical studies revealed that within the tumor
mass punctate labeling of cells co-staining for tumor markers were
much more prevalent with topical application of GB119 than with
systemically administered GB123. In contrast, most of the labeling
within the tumor mass for GB123 was associated with cells that
were negative for human tumor tissue markers and located in
apparent interstitial spaces within the tumor (Fig. 5). Of note CD-
11b positively staining cells also activated probe but only when
associated with cancer tissues. In each case, activation of GB119
was associated with regions of high Cat L expression, figure S2.
Cat L is regulated by endogenous inhibitors. Since the antibody
recognizes active as well as inactive Cat L, these data show that
Cat L while distributed within the tumor and normal brain is
differentially regulated and active within the brain and tumor-
brain interface only.
In several studies GB119 activation occurred on the contralat-
eral side of the brain. In all of these examples H&E staining of
tissue sections demonstrated ‘‘satellite’’ colonies of tumor cells on
the contralateral side of mouse brains unilaterally implanted with
tumors. However, the satellites cells were not labeled in animals
that received systemic application of GB123. From these
observations we hypothesize that infiltrating tumor cells are not
well vascularized and therefore proteases in these regions are
refractory to labeling by systemically administered probes.
Although generally these satellites would not be exposed during
human surgery, this data does suggest that topically administered
GB119 might be able to better identify tumor cells at the margin
that have not yet generated a vascular system then systemically
delivered imaging agents.
Another finding unique to the topical application of GB119 was
the robust tumor-margin labeling. Further, the labeling of the peri-
tumor space with GB119 (largely absent with GB123) was notably
diffuse. The diffuse labeling and definition of tumor margins after
topical application of GB119 may also be a result of secretion of
activated proteases into the interstitial space at the tumor margin
and due to the thicker sections used to obtain signal.
We also tested the utility of topical application to identify
‘‘missed tumor’’ in a mouse model for tumor resection. These
studies clearly demonstrated that topical application of GB119
following tumor resection could easily be used to identify tumor
tissue remaining in the resection cavity. It is of some concern that
in resection of tumors in a living animal blood and other fluids
entering the resection field might interfere with imaging. Our flank
tumor studies in living animals in which cavities were surgically
prepared within the tumors and imaged argue strongly that this is
not the case. We are currently developing a model for brain tumor
surgery in live mice to test this question directly. These studies
have also demonstrated that penetration of the probe into tissue is
limited. We, therefore, envision this technology to be used to
enhance surgical procedures. We envision normal surgical
procedures to remove ‘‘most’’ of the tumor mass and the topical
application of GB119 to be evoked when there is a question as to
the origin of tissue at the edge of the surgical margin. Using an
iterative process the surgeon would apply probe, surgically remove
fluorescing tissues and reapply the probe, repeating the process
until no probe activation is detected. Further, it is possible that this
technology may complement 5-ALA or MRI guided surgeries, first
cutting to 5-ALA/MRI negativity and then using topical GB119
Figure 6. Topical probe administration reveals remaining
tumor tissue in incomplete tumor resection. (a) Gross resection
of tumor growing on dorsal surface of brain was performed and GB119
was added directly to resulting cavity and imaged over time. H&E
stained section demonstrating the resulting tumor cavity with
remaining tumor cells (right). (b) Adjacent sections demonstrating
GB119-labeled tissue (false-colored red, left)i sa s s o c i a t e dw i t h
vimentin-positive tumor xenograft (false-colored green, right) but
not with normal brain tissue. (c) Higher magnification of cavity edge
from (b). Cell nuclei are labeled with DAPI (false-colored blue) in (b and
c). Section thickness 10 mm. Scale bar, 5 mm (a, left) 1 mm (a, right),
500 mm( b), 100 mm( c).
doi:10.1371/journal.pone.0033060.g006
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33060Figure 7. Rapid ex vivo activation of GB119 in human GBM biopsies. (a) Fold change in total TSAV across time for tumor biopsy pieces
compared to vehicle treatment alone (n=34). 14/15 of patients tested showed probe activation in at least one piece but only 34/42 (81%) of pieces
tested had activation greater than 4-fold that measured in normal human brain tissue. Inset is a representative unmixed false colored map of pixel
intensity representing activated GB119 in a tumor piece imaged over time. (b) Percent change in total signal of 3 pieces of normal brain frontal lobe
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tumor cells. We do not anticipate, although, that these techniques,
despite their potential to significantly improve GBM resections,
will result in surgical cures for patients. We do, however, believe
that the techniques described here can impact patient survival and
quality of life [5,7] and that reduction in tumor burden may
potentially impact other non-surgical therapies [13].
Here we explore the concept of topical application of imaging
probed to identify cancerous tissue during surgery, which was
recently introduced by Kobayashi and co-workers while this
manuscript was under review [29]. In this work Urano et al.
exploited a cancer-specific cell surface gamma-glutamyltranspep-
tidase to activate topically applied quenched imaging probe which
then became internalized, rapidly and selectively labeling a
number of different ovarian cancer lines both in vitro and in a
mouse model of disseminated ovarian cancer [29]. We demon-
strate that a NIRF quenched activity based imaging probe,
GB119, that targets tumor proteases can be used to differentiate
tumor cells from surrounding normal brain tissues. Tissue labeling
with fluorescently quenched activity based probes for the cysteine
cathepsins is highly protease selective and associates with peri-
tumor space and brain tumor margins, consistent with over-
expression of these proteases in these locations (figure S2 and
[21,22]). In studies utilizing human GBM tissue biopsies we
demonstrated that this technology is robust and has the potential
to be rapidly applied in the clinical setting. Taken together these
data strongly suggest that topical application of an optical imaging
probe directly into the surgical field is a feasible way to visualize
tumor tissues. Topical application of optical imaging agents should
improve cancer cell identification during surgery, enable near real-
time feedback on the completeness of the surgical resection and
therefore warrants further development.
Both topical and systemic administration of molecular imaging
probes to elaborate tumor tissues have demonstrated their
potential utility in mouse models with a human clinical trial now
underway to assess image-guided ovarian cancer surgery with
systemically administered probes. A driving force for acceptance of
intraoperative molecular probes into surgical use will be the
development of adequate imaging hardware technology, that will
allow the seamless translation and use of molecular imaging probes
in the surgical workflow [42,43,44,45,46]. As a field we should be
working towards a set of technical requirements both for agent
development and hardware development to allow for rapid
development and maximum utility of these agents and hardware
so cross platform use of agents and devices is possible.
Materials and Methods
Ethics Statement
All procedures were performed aseptically according to the
Case Western Reserve University Institutional Animal Care and
Use Committee (Case IACUC). The work performed in this
manuscript was approved by the Case IACUC; CWRU IACUC
Animal Experimental Protocol: 2009-0019.
Tissue culture, in vitro and ex vivo labeling
Human Gli36D5EGRF glioblastoma cell lines obtained as a gift
from Dr. EA Chiocca [47] were grown in DMEM (4.5 g/l glucose,
L-glutamine) supplemented with 10% fetal bovine serum and
180 U/ml penicillin, 180 mg/ml streptomycin, 0.45 mg/ml am-
photericin B (all reagents from Gibco, Invitrogen Corporation).
These cells constitutively over-express the vIII mutant forms of the
egfr gene and were selected for with the addition of 10 mg/ml of
puromycin. Cells were grown at 37uC in a 5% CO2 atmosphere
(Thermo Forma). For labeling experiments Gli36D5EGFR cells
were incubated with a 50 mM JPM-OEt, a general papain-family
inhibitor or 0.1% DMSO as a vehicle control. One hour later
1 mM of the indicated probe (GB119, GB123, or GB125) was
added for 4 hours. Samples were analyzed by SDS-PAGE and
Cy5 fluorescence was measured by scanning the gels with a
Typhoon fluorescent scanner (GE Healthcare). Ex vivo analysis of
labeling in Gli36D5EGFR flank tumor tissues was done in 10–12
day old tumors removed from mice. The tissue was divided into
pieces and each immersed in 10 mM GB119 for the 5, 10, 15, 20,
25, or 30 min or in 100% DMSO vehicle control for 30 minutes.
Additionally Gli36D5EGFR flank tumor was incubated for
15 minutes in either vehicle only (DMSO), GB111-NH2,a n
inhibitor of cathepsins B and L (inhibitor) [23], cathepsin L probe
only (GB119), or GB119 probe plus a 100-fold excess of GB111-
NH2 inhibitor (P+I). Post incubations samples were washed in
saline and analyzed by SDS-PAGE as above.
Cell Culture Preparation for Heterotopic and Orthotopic
Implants
Cell harvesting for brain and flank implantation was performed
after washing the cells in PBS and a short incubation with 1 ml
0.05% trypsin-EDTA (Gibco, Grand Islands, NY). Trypsin was
inactivated by the addition of serum-containing media and the
resulting cell suspension was centrifuged at 10006g for 3 minutes.
Cells were re-suspended in 10 ml PBS, counted and washed 2
times in PBS. The cells were re-suspended in 2 ml PBS/mouse for
brain implants and 250 ml PBS:matrigel (BD Biosciences) for flank
tumor implants per animal (3610
5 cells per animal for brain
implants and 3610
6 cells for flank tumor implants). Immediately
following the cell harvesting procedure animals were inoculated.
Animal Surgery
Athymic nude female mice (nu/nu, 6–8 weeks at time of surgery)
were bred and maintained at the Animal Resource Center at Case
Western Reserve University according to institutional policies
(CWRU IACUC Animal Experimental Protocol: 2009-0019). For
brain tumor implants, mice were anesthetized by intraperitoneal
injection of 50 mg/kg ketamine/xylazine and fitted into a
stereotaxic rodent frame (David Kopf Instruments, Tujunga,
CA). A small incision was made just lateral to midline to expose
the bregma suture. A small (1.0 mm) burr hole was drilled at
AP=+1, ML=22.5 from bregma. Glioblastoma cells (for
preparation see above) were slowly deposited at a rate of 1 ml/
minute in the right striatum at a depth of 23 mm from dura with
a1 0ml Hamilton syringe (26G blunt needle, Fisher Scientific).
The needle was slowly withdrawn and the incision was closed with
2–3 sutures. For flank tumor implants, mice were anesthetized
with inhaled isofluorane:oxygen for immobilization. The matri-
gel:cell mixture (for preparation see above) was loaded into a 1 ml
syringe fitted with a 26-gauge needle and kept on ice. The mixture
was injected subcutaneously in the right flank region of the mouse.
The needle was withdrawn and the animal was returned to the
cage.
compared to 3 pieces of tumor treated with GB119 from a single patient. Data are plotted as mean +/2 SD across time. (c) Left, representative images
from a single patient showing background and unmixed false colored maps of pixel intensity representing activated GB119. Right panel is fold
change in total signal/area/volume at 30 minutes for edge and center biopsy samples for 5 different patients. Scale bar, 5 mm.
doi:10.1371/journal.pone.0033060.g007
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Post imaging brains were fixed in 4% paraformaldehyde, 30%
sucrose protected and frozen in optimum cutting temperature
compound (OCT) for cryosectioning (Leica CM3050S). Sections
were collected serially at 10 or 25 mm cut directly on to slides and
stored at 280C until processing. For probe visualization slides
were warmed to room temperature for 10 minutes, washed in PBS
and coverslipped. Immunostaining was carried out after washes in
PBS with triton X 100 (PBSTX), blocking in appropriate normal
serum and incubation in primary antibody for 1–2 hours at room
temperature. For visualization of human tumor tissue, a human
anti-vimentin antibody (NeoMarkers) was used at 1:1000.
Fluorescent secondary antibody was labeled with Alexa 488
(Molecular Probes) so as to not interfere with the visualization of
the Cy5-labeled probe. For visualization of human and mouse
cathepsin L, Anti-human Cathepsin L antibody (RD Systems
Cat#: AF952) and Anti-mouse Cathepsin L antibody (RD
Systems Cat#: af1515) were used. All fluorescent sections were
counterstained with the nuclear dye DAPI (Sigma-Aldrich) and
coverslipped with fluorescent mounting media (Fluor-Gel, Elec-
tron Microscopy Sciences). Hematoxylin and eosin staining was
carried out on adjacent sections by standard procedures.
Microscopy
Fluorescent images were viewed with a Leica DM4000B upright
microscope (Filter cubes A4 bandpass (BP) 360/470, L5 BP 480/
527, and Y5 BP 620/700 for excitation and suppression filters,
respectively) and captured with a QImaging Retiga EXi Fast 1394
camera with a Mercury 100W bulb (CHIU Technical Corpora-
tion) as the light source. Camera and software (QImaging Q
Capture Pro version 5.1.1.14) were powered by a Dell Optiplex
GX620 desktop computer. Equal exposures and magnification
were used for documentation. Images were documented in 12-bit
gray scale and converted to false color jpeg images. Merging of
images taken with different fluorescent cubes was carried out in
Adobe Photoshop CS3 Extended version 10.0.1 by first converting
the original tif image to 8-bit, adjusting gray scale levels equally,
and merging channels to assign appropriate false colors. Image J
(NIH software) analysis of Cy5 fluorescence was carried out using
the original image, assigning equal threshold values for the DAPI
and the Cy5 images, then analyzing the area of the fluorescent
images. For each image, the Cy5 area was divided by the DAPI
area to obtain percent Cy5 fluorescence. Three mice were used for
the analysis taking values from a representative image of the tumor
center, edge, or invading cells.
Imaging and analysis
In vivo imaging of heterotopic flank tumors was performed under
inhaled isofluorane:oxygen. The skin overlying the tumor and the
tumor capsule was removed and 10 mM GB119 was topically
applied in 2–3 ml drops with a pipet tip directly on the tumor
tissue. The mice were euthanized immediately post imaging with
Fatal Plus. Ex vivo imaging was performed after euthanasia of the
mice and removal of the brain. The brain was either kept intact or
sectioned in 2 mm slices using an acrylic 1 mm coronal brain
matrix (Kent Scientific) prior to application of 4 ml of GB119/
hemisphere for the slice data. In studies where brains remained
intact 2 ml/site on tumor and normal brain were applied. Lateral
tail vein systemic GB123 injections (0.5 ml of a 50 mM solution,
33.3 ml DMSO and 66.6 ml PBS/mouse) were performed 19–
20 hours prior to imaging. The human tumor biopsies were
collected under a University Hospitals Case Medical Center
approved IRB protocol (#12-05-17). Tissue was collected in sterile
saline and pre-imaged followed by topical application of 3–10 ml
drops of 1 or 10 mM GB119 within 30 minutes of biopsy excision.
Fresh biopsies were obtained from 15 patients (1–3 pieces/patient;
total of 42 pieces). There was no difference in the change in
activation when 1 or 10 mM applications of probe were compared.
Spectral fluorescence images were obtained using the Maestro
T-
MIn-Vivo Imaging System (CRi, Inc., Woburn, MA). A band-pass
filter appropriate for the Cy5 (yellow filter set, Ex 575–605 nm,
Em 645; acquisition settings 630–850) was used for emission and
excitation light, respectively. The tunable filter was automatically
stepped in 10 nm increments while the camera captured images at
a constant exposure of 1000 ms. Fluorescence images were
acquired before treatment, immediately post treatment and every
five minutes for 30 minutes. At this time the treated areas were
washed with 100 ml of saline to remove any unbound probe and
imaged again at 35 minutes.
To compare signal intensities, regions of interest (ROI) were
selected over the entire treated area (tumor or non-tumor) and the
change in fluorescence signal over baseline was determined. To do
this baseline fluorescence was measured, the probe was applied
and the subsequent images were acquired. The spectral fluorescent
images consisting of autofluorescence spectra and activated
imaging probe were captured and unmixed based on their spectral
patterns using commercially available software (Maestro
TM
software 2.4.0, Cri, Woburn MA). Total signal in the ROI in
photons measured at the surface of the animal was divided by the
area the probe was applied to (in pixels) then divided by volume of
the probe in order to compare activation between animals and
imaging experiments where different amounts of probe were
administered. Spectral libraries were generated by assigning
spectral peaks to the tissue background fluorescence (either ex vivo
tissue or mouse whole body), background from the imaging stage,
unactivated quenched probe applied to the skin, and activated
probe over tumor at maximal activation. The spectral libraries
were manually computed using the Maestro
TM software, with each
mouse or tissue used as their own background control. A spectral
shift was found between the unactivated probe and activated
probe (figure S3 and S4). This difference allowed us to
differentiate between activated and unactivated probe and all
analysis and quantitation of activated probe was based on the
spectral library determined from this shift.
Statistics
Coefficients of variation (CV’s) were first determined for total
signal (TS), total signal/volume of probe (TSV), total signal/area
probe was applied to (TSA), and total signal/volume/area
(TSVA). TS and TSV tended to have higher CV’s than TSA or
TSAV, indicating that correcting for area helps reduce inherent
between-animal variability. For all analysis the measure of TSVA
was used. For the flank tumor data, the Wilcoxon signed rank test
was used to test whether the signal at each of the time points 1, 5,
15, 30 and 35 differed from the signal at time 0. For the orthotopic
brain slice, dorsal surface, and human biopsy data, to better meet
assumptions of normality underlying the statistical methods, the
logarithms of total signal/area/volume were used in the analysis.
These data were analyzed using a mixed linear repeated measures
model, and means of control and treated were compared at each
timepoint, with Bonferroni correction for multiple testing at times
.0. Data are presented as means and standard deviation on the
original untransformed scale.
Supporting Information
Figure S1 Cat L labeling resulting from in vivo topical
application of GB119 to exposed flank tumors. In vivo
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(lane 3) GB119 or no treatment (lanes 2, 4). Flank tumors were
treated topically with probe and the red areas were dissected out
and analyzed by SDS-PAGE as in figure 1. Specific Cathepsin L
bands are indicated as follows; Cat L sc. Minimal tissues could be
resected and therefore only the abundantly labeled Cat L sc was
visible.
(TIF)
Figure S2 Immunohistochemical analysis of probe
specificity for cathepsin L protein following topical
application to explanted brain. Twenty-five mm sections
were used to visualize covalently bound GB119 in (a) the tumor
center (b) the tumor edge, and (c) the contralateral hemisphere
(columns labeled Tumor center, Tumor edge, and Contralateral
hemisphere). Immunostaining was performed to identify either (d)
human cathepsin L in the xenograft tumor or (e) mouse cathepsin
L in the host brain at the tumor edge, or (f) in the contralateral
hemisphere. Panels (g–i) are DAPI counterstained sections to
visualize cell nuclei/density. Panels (j–l) are merged images of
GB119, cathepsin L protein and Dapi for tumor center, tumor
edge and contralateral side, respectively. These data reveal yellow
cells both at the center of the tumor and at the tumor’s edge
suggesting GB119 covalently binds to active cathepsin L enzyme
both within and around the tumor, but not in the normal brain
surrounding the tumor nor in the contralateral hemisphere. These
data also suggest that mouse tissues, likely macrophages,
contribute to the Cat L activity at the tumors edge, also see
figure 4 in the manuscript. Scale bar=100 mm.
(TIF)
Figure S3 Determination of spectral library for analysis
of activated GB119. (a) Monochromatic image showing
heterotopic Gli36D5EGFR flank tumor and tube containing
5 ml of 10 mM GB119 (arrow) (b) Unmixed spectral library from
mouse body (white line), imaging stage (black line) both chosen
from the before treatment image. The blue line is unactivated
GB119 chosen from both the tube (arrow) and probe applied to
skin (arrow head) in c immediately after probe application. The
green line was chosen from probe over tumor at 30 minutes
(arrow) in d. Images in c and d are from the raw data in the image
cube. A measurable shift in the spectral profile of the activated
(green line) compared to unactivated (blue line) probe was
observed.
(TIF)
Figure S4 Use of spectral library to determine activa-
tion of GB119. (a) Spectral library showing mouse background
(white line), imaging stage background (black line), activated
GB119 subtracted from mouse background (red line), and
unactivated GB119 subtracted from mouse background (magenta
line). Library derived as in figure S3 above. (b) Image is the
unmixed composite showing the false-colored hotmap of the
activated probe (left side) or the unactivated probe (right side) over
the background image at 30 min. (c) Time course of total signal of
activated GB119 over time in both tumor (solid line) and skin
(dotted line). Spectral profiles derived here were used to analyze all
in vivo and ex vivo imaging experiments.
(TIF)
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